Search

AV-COVID-19

The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration. … AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF).

SCB-2019

SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. … As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine.

CoronaVac

It was developed by propagating the SARS-CoV-2 CN2 strain inside Vero Cells and inactivating it with B-propiolactone[A219481;A219758]. … CoronaVac, previously known as PiCoVacc, is a SARS-CoV-2 purified, inactivated, and adsorbed vaccine candidate developed by SinoVac Biotech Corporation[A219758].

BBIBP-CorV

BBIBP-CorV vaccine contains a SARS-CoV-2 strain inactivated inside Vero Cells. … Investigation shows this vaccine induces neutralizing antibodies in several mammalian species while also showing protective efficacy with SARS-CoV-2 challenge in rhesus macaques[A219763].

CIGB-258 peptide

CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant.

Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine

Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was developed using domains of viral structural proteins and a polyprotein protease. … Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these engineered minigenes to express viral proteins, modify artificial antigen presenting cells (aAPC), and activate T-cells

COVID19 s-vax loaded autologous dendritic cell vaccine

The rationale is that loading a DC cell with SARS-Cov-2 antigens and administering it as a vaccine can induce a more prolific immune response. … These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine.

Fluocortolone caproate

Pralsetinib

[A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment … It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986]

Lecithin

A complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.